{{Rsnum
|rsid=3738815
|Gene=ATP13A2
|Chromosome=1
|position=16988207
|Orientation=minus
|GMAF=0.3081
|Gene_s=ATP13A2
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 0.9 | 29.2 | 69.9
| HCB | 32.8 | 49.6 | 17.5
| JPT | 28.3 | 54.9 | 16.8
| YRI | 1.4 | 15.6 | 83.0
| ASW | 0.0 | 28.1 | 71.9
| CHB | 32.8 | 49.6 | 17.5
| CHD | 21.1 | 44.0 | 34.9
| GIH | 8.9 | 32.7 | 58.4
| LWK | 0.9 | 30.9 | 68.2
| MEX | 14.0 | 50.9 | 35.1
| MKK | 7.1 | 43.6 | 49.4
| TSI | 2.0 | 34.3 | 63.7
| HapMapRevision=28
}}{{PMID Auto
|PMID=22285144
|Title=ATP13A2 (PARK9) polymorphisms influence the neurotoxic effects of manganese
|OA=1
}}

{{PMID|19085912|OA=1
}} ATP13A2 variability in Parkinson disease.

{{ClinVar
|ALT=T
|CHROM=1
|CLNACC=RCV000116437.1
|CLNALLE=1
|CLNDBN=AllHighlyPenetrant
|CLNDSDB=MedGen
|CLNDSDBID=CN169374
|CLNHGVS=NC_000001.11:g.16988207C>T
|CLNORIGIN=1
|CLNSIG=2
|CLNSRC=ClinVar
|CLNSRCID=NM_022089.2:c.2790G>A
|Disease=AllHighlyPenetrant
|FwdALT=A
|FwdREF=G
|GENEINFO=ATP13A2:23400
|GENE_ID=23400
|GENE_NAME=ATP13A2
|REF=C
|RSPOS=16988207
|Reversed=1
|SAO=0
|SSR=0
|Tags=RV;PM;PMC;S3D;SLO;REF;SYN;ASP;VLD;G5A;G5;HD;GNO;KGPhase1;KGPilot123;KGPROD;OTHERKG;PH3
|VC=SNV
|VP=0x05032800030517051f000100
|WGT=1
|dbSNPBuildID=107
|rsid=3738815
}}
{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}